Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejvs.2024.04.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of surgical technique on gastroesophageal reflux disease after laparoscopic sleeve gastrectomy: a nationwide observational study.
Surg Obes Relat Dis
October 2024
Department of Surgery, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Background: Laparoscopic sleeve gastrectomy (LSG) has gained increasing popularity worldwide, yet concerns persist regarding the development of gastroesophageal reflux disease (GERD) postoperatively.
Objectives: This study aimed to evaluate the influence of technical aspects of LSG, specifically bougie size and distance from the pylorus to resection line edge, on the risk of developing symptomatic GERD within 2years following surgery.
Setting: Data from the Scandinavian Obesity Surgery Registry (SOReg) and the National Prescribed Drug Register were utilized for this analysis.
Myopia control with orthokeratology lenses. A 3-year follow-up study including a cross-over design: Clinical study Of Near-sightedness; TReatment with Orthokeratology Lenses 2 (CONTROL2 study).
Acta Ophthalmol
October 2024
Department of Ophthalmology, University Hospital of Southern Denmark, Vejle Hospital, Vejle, Denmark.
Purpose: The purpose of this study is to investigate 3-year efficacy of orthokeratology lenses (OKL) in controlling axial length progression in myopic Scandinavian children. Through a cross-over design of the control group to compare the treatment efficacy in younger versus older children, with the latter having higher cycloplegic spherical refractive error (cSEQ) at treatment initiation. Further, the study aimed to evaluate the safety of the treatment.
View Article and Find Full Text PDFEmpagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study.
J Diabetes Res
October 2024
Department of Cardiology, Oslo University Hospital Ullevål 0450, Oslo, Norway.
Article Synopsis
- The EMPRISE study evaluated empagliflozin's effectiveness in reducing various health risks (including all-cause mortality and hospitalization for heart failure) compared to DPP-4 inhibitors in patients with type 2 diabetes across four Nordic countries.
- Using a noninterventional, multicountry cohort design and propensity score matching, the study analyzed data from 43,695 patients and employed Cox proportional hazards regression for risk assessment.
- Results indicated that patients starting empagliflozin had a significantly lower risk of all-cause mortality, hospitalization for heart failure, cardiovascular mortality, and end-stage renal disease, though no significant differences were found for stroke or myocardial infarction.
Single-blinded, randomised, parallel-group, controlled trial comparing the efficacy and cost-effectiveness of therapist- and self-guided internet-delivered behavioural activation versus treatment as usual for adolescents with mild to moderate depression: study protocol.
BMJ Open
October 2024
Department of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden.
Introduction: The number of adolescents seeking professional help for depression is increasing and, despite advances in treatment, large unmet treatment needs remain. In the current protocol, we describe the design and methodology of a randomised controlled trial (RCT) to evaluate the clinical efficacy of two forms of internet-delivered behavioural activation (I-BA), with and without therapist support, in reducing depressive symptoms, compared with treatment as usual (TAU). Secondary objectives include examining the 12-month maintenance of the treatment effects and conducting a health economic evaluation of the interventions.
View Article and Find Full Text PDFAdding Evidence to an Evidence-Based Classification for Recurrent Weight Gain after Bariatric and Metabolic Surgery from a Norwegian National Registry.
Obes Surg
October 2024
Department of Surgery, Spaarne Gasthuis Hoofddorp, Spaarnepoort 1, 2134 TM, Hoofddorp, The Netherlands.
Background: In 2023, the first evidence-based classification for recurrent weight gain (RWG) after metabolic and bariatric surgery was introduced. It uses early and late follow-up weight loss benchmarks based on standard deviations (SD) of percentage total weight loss(%TWL) results from the large Dutch Audit for Treatment of Obesity (DATO) registry (n > 18,000). We aimed to validate this classification and confirm its clinical relevance with an external cohort.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!